Purpose

The incidence of breast cancer worldwide has been on the rise since the late 1970s, and it has become a common tumor that threatens women’s health. Aminoglutethimide (AG) is a common treatment of breast cancer. However, current treatments require frequent dosing that results in unstable plasma concentration and low bioavailability, risking serious adverse reactions. Our goal was to develop a molecularly imprinted polymer (MIP) based delivery system to control the release of AG and demonstrate the availability of this drug delivery system (DDS), which was doped with carbon nanotube with aid of metal-organic gel.

Methods

Preparation of MIP was optimized by key factors including composition of formula, ratio of monomers and drug loading concentration.

Results

By using multi-walled carbon nanotubes (MWCNT) and metal-organic gels (MOGs), MIP doubled the specific surface area, pore volume tripled and the IF was 1.6 times than the reference. Compared with commercial tablets, the relative bioavailability was 143.3% and a more stable release appeared.

Conclusions

The results highlight the influence of MWCNT and MOGs on MIP, which has great potential as a DDS.

中文翻译：

---

掺杂有碳纳米管的分子印迹聚合物，借助金属有机凝胶用于药物输送系统。

目的

自1970年代后期以来，全球乳腺癌的发病率一直在上升，并且已成为威胁妇女健康的常见肿瘤。氨基谷氨酰胺（AG）是乳腺癌的常见治疗方法。然而，当前的治疗需要频繁的给药，这导致不稳定的血浆浓度和低的生物利用度，存在严重不良反应的风险。我们的目标是开发一种基于分子印迹聚合物（MIP）的输送系统，以控制AG的释放并证明该药物输送系统（DDS）的可用性，该系统通过金属有机凝胶掺杂了碳纳米管。

方法

通过配方组成，单体比例和载药量等关键因素优化了MIP的制备。

结果

通过使用多壁碳纳米管（MWCNT）和金属有机凝胶（MOG），MIP的比表面积增加了一倍，孔体积增加了三倍，IF值是参考值的1.6倍。与市售片剂相比，相对生物利用度为143.3％，并且出现了更稳定的释放。

结论

结果突出了MWCNT和MOG对MIP的影响，MIP具有作为DDS的巨大潜力。